



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JANUARY 19, 2023

PTAS

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

507699473

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 01/17/2023

REEL/FRAME: 062400/0616
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 79275-30004.00

ASSIGNOR:

LEE, PATRICK SANG TAE

DOC DATE: 01/10/2023

ASSIGNOR:

EWING, TODD JONATHAN AUGUST

DOC DATE: 01/09/2023

ASSIGNOR:

REID, ADAM NEIL

DOC DATE: 01/09/2023

ASSIGNOR:

SINZ, CHRISTOPHER JOSEPH

DOC DATE: 01/10/2023

ASSIGNOR:

ZHANG, BIRONG

DOC DATE: 01/10/2023

ASSIGNOR:

BRONNER, SARAH M.

DOC DATE: 01/09/2023

ASSIGNOR:

MORGANS, DAVID JOHN, JR.

DOC DATE: 01/10/2023

ASSIGNOR:
HOEK, MAARTEN

DOC DATE: 01/10/2023

ASSIGNOR:
ASSIMON, VICTORIA ANNE

DOC DATE: 01/09/2023

ASSIGNOR:
ZIEBENHAUS, CHRIS

DOC DATE: 01/09/2023

ASSIGNOR:
SCHAMMEL, ALEXANDER WAYNE

DOC DATE: 01/09/2023

ASSIGNEE:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 63300592

FILING DATE: 01/18/2022

PATENT NUMBER:

ISSUE DATE:

TITLE: APOL1 INHIBITORS AND METHODS OF USE

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7746617

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PATRICK SANG TAE LEE	01/10/2023
TODD JONATHAN AUGUST EWING	01/09/2023
ADAM NEIL REID	01/09/2023
CHRISTOPHER JOSEPH SINZ	01/10/2023
BIRONG ZHANG	01/10/2023
SARAH M. BRONNER	01/09/2023
DAVID JOHN MORGANS JR.	01/10/2023
MAARTEN HOEK	01/10/2023
VICTORIA ANNE ASSIMON	01/09/2023
CHRIS ZIEBENHAUS	01/09/2023
ALEXANDER WAYNE SCHAMMEL	01/09/2023
RECEIVING PARTY DATA	
Name:	MAZE THERAPEUTICS, INC.
Street Address:	171 OYSTER POINT BLVD, SUITE 300
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	63300592
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 648-4782
Email:	nmendoza@mofo.com
Correspondent Name:	MARK MCBRIAR
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	200 CLARENDON STREET, 21ST FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02116

ASSIGNMENT

This assignment is by:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
4. Christopher Joseph Sinz
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
7. David John Morgans Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco California
United States of America
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California 94080
United States of America

(each referred to in this Assignment as "Assignor"), whose residence or mailing address information is listed above.

This Assignment is to:

Assignee: Maze Therapeutics, Inc.
Address: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
A juristic entity duly organized under and pursuant to the laws of:

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions in:

APOL1 INHIBITORS AND METHODS OF USE

which are set forth in:

Serial No.: 63/300,592 Filing Date: January 18, 2022
(which identifying information may be added after execution)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and

any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: _____	Signature: _____	Patriek Sang Tac Lee
Date: <u>01-09-2023</u>	Signature: _____	Todd Jonathan August Ewing
Date: _____	Signature: _____	Adam Neil Reid
Date: _____	Signature: _____	Christopher Joseph Sinz
Date: _____	Signature: _____	Birong Zhang

any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.



4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: <u>1/10/23</u>	Signature: 	Patrick Sang Tae Lee
Date: _____	Signature: _____	Todd Jonathan August Ewing
Date: <u>1/9/23</u>	Signature: 	Adam Neil Reid
Date: <u>1/10/23</u>	Signature: 	Christopher Joseph Sinz
Date: <u>1/10/23</u>	Signature: 	Birong Zhang


Date: _____	Signature: _____	Sarah M. Bronner
Date: _____	Signature: _____	David John Morgans Jr.
Date: _____	Signature: _____	Maarten Hoek
Date: <u>01/09/23</u>	Signature: <u>Victoria Anne Assimon</u>	Victoria Anne Assimon
Date: _____	Signature: _____	Chris Ziebenhaus
Date: _____	Signature: _____	Alexander Wayne Schammel

ASSIGNEE:


Date: _____	Signature: _____	Name: _____
		Title: _____
		Company: Maze Therapeutics, Inc.

Date: 1/9/23 Signature: 
Sarah M. Bronner

Date: 1/10/23 Signature: 
David John Morgans Jr.

Date: 1/10/23 Signature: 
Maarten Hoek

Date: _____ Signature: _____
Victoria Anne Assimon

Date: 1/9/23 Signature: 
Chris Ziebert

Date: 1/9/23 Signature: 
Alexander Wayne Schammel

ASSIGNEE:

Date: 1/12/23 Signature: 
Name: Atul Dandekar
Title: Chief Strategy Officer
Company: Maze Therapeutics, Inc.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 15, 2022

PTAS

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

507278618

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 05/11/2022

REEL/FRAME: 059895/0136
NUMBER OF PAGES: 9

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 79275-30004.01

ASSIGNOR:

LEE, PATRICK SANG TAE

DOC DATE: 04/26/2022

ASSIGNOR:

EWING, TODD JONATHAN AUGUST

DOC DATE: 04/25/2022

ASSIGNOR:

REID, ADAM NEIL

DOC DATE: 04/26/2022

ASSIGNOR:

SINZ, CHRISTOPHER JOSEPH

DOC DATE: 04/26/2022

ASSIGNOR:

ZHANG, BIRONG

DOC DATE: 04/26/2022

ASSIGNOR:

BRONNER, SARAH M.

DOC DATE: 04/26/2022

ASSIGNOR:

MORGANS, DAVID JOHN, JR.

DOC DATE: 04/26/2022

ASSIGNOR:
HOEK, MAARTEN

DOC DATE: 04/26/2022

ASSIGNOR:
ASSIMON, VICTORIA ANNE

DOC DATE: 04/26/2022

ASSIGNOR:
ZIEBENHAUS, CHRIS

DOC DATE: 04/26/2022

ASSIGNOR:
SCHAMMEL, ALEXANDER WAYNE

DOC DATE: 04/26/2022

ASSIGNEE:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 63311668

FILING DATE: 02/18/2022

PATENT NUMBER:

ISSUE DATE:

TITLE: APOL1 INHIBITORS AND METHODS OF USE

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT																								
NATURE OF CONVEYANCE:	ASSIGNMENT																								
CONVEYING PARTY DATA																									
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>PATRICK SANG TAE LEE</td><td>04/26/2022</td></tr><tr><td>TODD JONATHAN AUGUST EWING</td><td>04/25/2022</td></tr><tr><td>ADAM NEIL REID</td><td>04/26/2022</td></tr><tr><td>CHRISTOPHER JOSEPH SINZ</td><td>04/26/2022</td></tr><tr><td>BIRONG ZHANG</td><td>04/26/2022</td></tr><tr><td>SARAH M. BRONNER</td><td>04/26/2022</td></tr><tr><td>DAVID JOHN MORGANS, JR.</td><td>04/26/2022</td></tr><tr><td>MAARTEN HOEK</td><td>04/26/2022</td></tr><tr><td>VICTORIA ANNE ASSIMON</td><td>04/26/2022</td></tr><tr><td>CHRIS ZIEBENHAUS</td><td>04/26/2022</td></tr><tr><td>ALEXANDER WAYNE SCHAMMEL</td><td>04/26/2022</td></tr></tbody></table>	Name	Execution Date	PATRICK SANG TAE LEE	04/26/2022	TODD JONATHAN AUGUST EWING	04/25/2022	ADAM NEIL REID	04/26/2022	CHRISTOPHER JOSEPH SINZ	04/26/2022	BIRONG ZHANG	04/26/2022	SARAH M. BRONNER	04/26/2022	DAVID JOHN MORGANS, JR.	04/26/2022	MAARTEN HOEK	04/26/2022	VICTORIA ANNE ASSIMON	04/26/2022	CHRIS ZIEBENHAUS	04/26/2022	ALEXANDER WAYNE SCHAMMEL	04/26/2022	
Name	Execution Date																								
PATRICK SANG TAE LEE	04/26/2022																								
TODD JONATHAN AUGUST EWING	04/25/2022																								
ADAM NEIL REID	04/26/2022																								
CHRISTOPHER JOSEPH SINZ	04/26/2022																								
BIRONG ZHANG	04/26/2022																								
SARAH M. BRONNER	04/26/2022																								
DAVID JOHN MORGANS, JR.	04/26/2022																								
MAARTEN HOEK	04/26/2022																								
VICTORIA ANNE ASSIMON	04/26/2022																								
CHRIS ZIEBENHAUS	04/26/2022																								
ALEXANDER WAYNE SCHAMMEL	04/26/2022																								
RECEIVING PARTY DATA																									
<table border="1"><tr><td>Name:</td><td>MAZE THERAPEUTICS, INC.</td></tr><tr><td>Street Address:</td><td>171 OYSTER POINT BLVD, SUITE 300</td></tr><tr><td>City:</td><td>SOUTH SAN FRANCISCO</td></tr><tr><td>State/Country:</td><td>CALIFORNIA</td></tr><tr><td>Postal Code:</td><td>94080</td></tr></table>	Name:	MAZE THERAPEUTICS, INC.	Street Address:	171 OYSTER POINT BLVD, SUITE 300	City:	SOUTH SAN FRANCISCO	State/Country:	CALIFORNIA	Postal Code:	94080															
Name:	MAZE THERAPEUTICS, INC.																								
Street Address:	171 OYSTER POINT BLVD, SUITE 300																								
City:	SOUTH SAN FRANCISCO																								
State/Country:	CALIFORNIA																								
Postal Code:	94080																								
PROPERTY NUMBERS Total: 1																									
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>63311668</td></tr></tbody></table>	Property Type	Number	Application Number:	63311668																					
Property Type	Number																								
Application Number:	63311668																								
CORRESPONDENCE DATA																									
Fax Number: (617)830-0142																									
Phone: (617) 648-4782																									
Email: nmendoza@mofo.com																									
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>																									
Correspondent Name: MARK MCBRIAR																									
Address Line 1: MORRISON & FOERSTER LLP																									
Address Line 2: 200 CLARENDON STREET, 21ST FLOOR																									
Address Line 4: BOSTON, MASSACHUSETTS 02116																									

ATTORNEY DOCKET NUMBER:	79275-30004.01
NAME OF SUBMITTER:	MARK MCBRIAR
Signature:	/Mark McBriar/
Date:	05/11/2022
Total Attachments: 7 source=79275-30004.01 Assignment#page1.tif source=79275-30004.01 Assignment#page2.tif source=79275-30004.01 Assignment#page3.tif source=79275-30004.01 Assignment#page4.tif source=79275-30004.01 Assignment#page5.tif source=79275-30004.01 Assignment#page6.tif source=79275-30004.01 Assignment#page7.tif	
RECEIPT INFORMATION EPAS ID: PAT7325539 Receipt Date: 05/11/2022	

ASSIGNMENT

This assignment is by:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
4. Christopher Joseph Sinz
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
7. David John Morgans, Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300
South San Francisco, California 94080
United States of America
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco California
United States of America
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California 94080
United States of America

(each referred to in this Assignment as "Assignor"), whose residence or mailing address information is listed above.

This Assignment is to:

Assignee: Maze Therapeutics, Inc.
Address: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), which desires to acquire the Assignor's entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions in:

APOL1 INHIBITORS AND METHODS OF USE

which are set forth in:

Serial No.: 63/311,668 Filing Date: February 18, 2022
(which identifying information may be added after execution)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, provisional application and application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said provisional application and application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said provisional application and application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said provisional application and application for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said provisional application and application for letters patent; (b) any and all non-provisionals, divisions, continuations, or continuations-in-part claiming priority thereto or the benefit thereof, or any substitution of any such applications, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.





4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: <u>4/26/22</u>	Signature: 	Patrick Sang Tae Lee
Date: _____	Signature: _____	Todd Jonathan August Ewing
Date: <u>4/26/22</u>	Signature: 	Adam Neil Reid
Date: <u>04/26/22</u>	Signature: 	Christopher Joseph Sinz
Date: <u>04/26/22</u>	Signature: 	Birong Zhang
Date: <u>4/26/22</u>	Signature: 	Sarah M. Brommer
Date: <u>04/26/22</u>	Signature: 	David John Morgans, Jr.
Date: <u>4/26/22</u>	Signature: 	Maarten Hoek

ASSIGNMENT

This assignment is by:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
4. Christopher Joseph Sinz
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
7. David John Morgans, Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300
South San Francisco, California 94080
United States of America
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco California
United States of America
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California 94080
United States of America

(each referred to in this Assignment as "Assignor"), whose residence or mailing address information is listed above.

This Assignment is to:

Assignee: Maze Therapeutics, Inc.
Address: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), which desires to acquire the Assignor's entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions in:

APOL1 INHIBITORS AND METHODS OF USE

which are set forth in:

Serial No.: 63/311,668 Filing Date: February 18, 2022
(which identifying information may be added after execution)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, provisional application and application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said provisional application and application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said provisional application and application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said provisional application and application for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said provisional application and application for letters patent; (b) any and all non-provisionals, divisions, continuations, or continuations-in-part claiming priority thereto or the benefit thereof, or any substitution of any such applications, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.



5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: _____	Signature: _____	Patrick Sang Tae Lee
Date: <u>04/25/2022</u>	Signature: _____	<i>Todd Jonathan August Ewing</i> Todd Jonathan August Ewing
Date: _____	Signature: _____	Adam Neil Reid
Date: _____	Signature: _____	Christopher Joseph Sinz
Date: _____	Signature: _____	Birong Zhang
Date: _____	Signature: _____	Sarah M. Bronner
Date: _____	Signature: _____	David John Morgans, Jr.
Date: _____	Signature: _____	Maarten Hoek

Date: 04/26/22 Signature: 
Victoria Anne Assimon
Date: 4/26/22 Signature: 
Chris Ziebenhans
Date: 4/26/22 Signature: 
Alexander Wayne Schammel

ASSIGNEE:

Date: 5/2/22 Signature: 
Name: Tara Nickerson
Title: Chief Business Officer
Company: Maze Therapeutics, Inc.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JANUARY 19, 2023

PTAS

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

507699470

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 01/17/2023

REEL/FRAME: 062400/0605
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 79275-30004.02

ASSIGNOR:

LEE, PATRICK SANG TAE

DOC DATE: 01/10/2023

ASSIGNOR:

EWING, TODD JONATHAN AUGUST

DOC DATE: 01/09/2023

ASSIGNOR:

REID, ADAM NEIL

DOC DATE: 01/09/2023

ASSIGNOR:

SINZ, CHRISTOPHER JOSEPH

DOC DATE: 01/10/2023

ASSIGNOR:

ZHANG, BIRONG

DOC DATE: 01/10/2023

ASSIGNOR:

BRONNER, SARAH M.

DOC DATE: 01/09/2023

ASSIGNOR:

MORGANS, DAVID JOHN, JR.

DOC DATE: 01/10/2023

ASSIGNOR:
HOEK, MAARTEN

DOC DATE: 01/10/2023

ASSIGNOR:
ASSIMON, VICTORIA ANNE

DOC DATE: 01/09/2023

ASSIGNOR:
ZIEBENHAUS, CHRIS

DOC DATE: 01/09/2023

ASSIGNOR:
SCHAMMEL, ALEXANDER WAYNE

DOC DATE: 01/09/2023

ASSIGNEE:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 63332553

FILING DATE: 04/19/2022

PATENT NUMBER:

ISSUE DATE:

TITLE: APOL1 INHIBITORS AND METHODS OF USE

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7746614

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PATRICK SANG TAE LEE	01/10/2023
TODD JONATHAN AUGUST EWING	01/09/2023
ADAM NEIL REID	01/09/2023
CHRISTOPHER JOSEPH SINZ	01/10/2023
BIRONG ZHANG	01/10/2023
SARAH M. BRONNER	01/09/2023
DAVID JOHN MORGANS JR.	01/10/2023
MAARTEN HOEK	01/10/2023
VICTORIA ANNE ASSIMON	01/09/2023
CHRIS ZIEBENHAUS	01/09/2023
ALEXANDER WAYNE SCHAMMEL	01/09/2023
RECEIVING PARTY DATA	
Name:	MAZE THERAPEUTICS, INC.
Street Address:	171 OYSTER POINT BLVD, SUITE 300
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	63332553
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 648-4782
Email:	nmendoza@mofo.com
Correspondent Name:	MARK MCBRIAR
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	200 CLARENDON STREET, 21ST FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02116

ASSIGNMENT

This assignment is by:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
4. Christopher Joseph Sinz
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
7. David John Morgans, Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300
South San Francisco, California 94080
United States of America
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco California
United States of America
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California 94080
United States of America

(each referred to in this Assignment as “Assignor”), whose residence or mailing address information is listed above.

This Assignment is to:

Assignee: Maze Therapeutics, Inc.
Address: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as “Assignee”), which desires to acquire the Assignor’s entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions in:

APOL1 INHIBITORS AND METHODS OF USE

which are set forth in:

Serial No.: 63/332,553 Filing Date: April 19, 2022
(which identifying information may be added after execution)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor’s entire right, title and interest in and to the above-mentioned inventions, provisional application and application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said provisional application and application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said provisional application and application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said provisional application and application for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said provisional application and application for letters patent; (b) any and all non-provisionals, divisions, continuations, or continuations-in-part claiming priority thereto or the benefit thereof, or any substitution of any such applications, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.






4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: <u>1/10/23</u>	Signature: 	Patrick Sang Tae Lee
Date: _____	Signature: _____	Todd Jonathan August Ewing
Date: <u>1/9/23</u>	Signature: 	Adam Neil Reid
Date: <u>1/10/23</u>	Signature: 	Christopher Joseph Simz
Date: <u>1/10/23</u>	Signature: 	Birong Zhang
Date: <u>1/9/23</u>	Signature: 	Sarah M. Bronner
Date: <u>1/10/23</u>	Signature: 	David John Morgans, Jr.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said provisional application and application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said provisional application and application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said provisional application and application for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said provisional application and application for letters patent; (b) any and all non-provisionals, divisions, continuations, or continuations-in-part claiming priority thereto or the benefit thereof, or any substitution of any such applications, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: _____	Signature: _____	Patrick Sang Jae Lee
Date: <u>01-09-2023</u>	Signature: _____	Todd Jonathan August Ewing
Date: _____	Signature: _____	Adam Neil Reid
Date: _____	Signature: _____	Christopher Joseph Sinz
Date: _____	Signature: _____	Birong Zhang
Date: _____	Signature: _____	Sarah M. Bronner
Date: _____	Signature: _____	David John Morgans, Jr.


Date: _____	Signature: _____	Maarten Hoek
Date: <u>01/09/23</u>	Signature: <u>Victoria Anne Assimon</u>	Victoria Anne Assimon
Date: _____	Signature: _____	Chris Ziebenhaus
Date: _____	Signature: _____	Alexander Wayne Schammel


ASSIGNEE:

Date: _____	Signature: _____	Name: _____
		Title: _____
		Company: Maze Therapeutics, Inc.


Date: 1/10/23 Signature: 
Maarten Hoek

Date: _____ Signature: _____
Victoria Anne Assimon

Date: 1/19/23 Signature: 
Chris Ziebenhaus

Date: 1/19/23 Signature: 
Alexander Wayne Schammel

ASSIGNEE:

Date: 1/12/23 Signature: 
Name: Atul Dandekar
Title: Chief Strategy Officer
Company: Maze Therapeutics, Inc.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JANUARY 19, 2023

PTAS

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

507699466

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 01/17/2023

REEL/FRAME: 062400/0591
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 79275-30004.03

ASSIGNOR:

LEE, PATRICK SANG TAE

DOC DATE: 01/10/2023

ASSIGNOR:

EWING, TODD JONATHAN AUGUST

DOC DATE: 01/09/2023

ASSIGNOR:

REID, ADAM NEIL

DOC DATE: 01/09/2023

ASSIGNOR:

SINZ, CHRISTOPHER JOSEPH

DOC DATE: 01/10/2023

ASSIGNOR:

ZHANG, BIRONG

DOC DATE: 01/10/2023

ASSIGNOR:

BRONNER, SARAH M.

DOC DATE: 01/09/2023

ASSIGNOR:

MORGANS, DAVID JOHN, JR.

DOC DATE: 01/10/2023

ASSIGNOR:
HOEK, MAARTEN

DOC DATE: 01/10/2023

ASSIGNOR:
ASSIMON, VICTORIA ANNE

DOC DATE: 01/09/2023

ASSIGNOR:
ZIEBENHAUS, CHRIS

DOC DATE: 01/09/2023

ASSIGNOR:
SCHAMMEL, ALEXANDER WAYNE

DOC DATE: 01/09/2023

ASSIGNEE:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 63400359

FILING DATE: 08/23/2022

PATENT NUMBER:

ISSUE DATE:

TITLE: APOL1 INHIBITORS AND METHODS OF USE

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7746610

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PATRICK SANG TAE LEE	01/10/2023
TODD JONATHAN AUGUST EWING	01/09/2023
ADAM NEIL REID	01/09/2023
CHRISTOPHER JOSEPH SINZ	01/10/2023
BIRONG ZHANG	01/10/2023
SARAH M. BRONNER	01/09/2023
DAVID JOHN MORGANS JR.	01/10/2023
MAARTEN HOEK	01/10/2023
VICTORIA ANNE ASSIMON	01/09/2023
CHRIS ZIEBENHAUS	01/09/2023
ALEXANDER WAYNE SCHAMMEL	01/09/2023
RECEIVING PARTY DATA	
Name:	MAZE THERAPEUTICS, INC.
Street Address:	171 OYSTER POINT BLVD, SUITE 300
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	63400359
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 648-4782
Email:	nmendoza@mofo.com
Correspondent Name:	MARK MCBRIAR
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	200 CLARENDON STREET, 21ST FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02116

ASSIGNMENT

This assignment is by:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
4. Christopher Joseph Sinz
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
7. David John Morgans, Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300
South San Francisco, California 94080
United States of America
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco California
United States of America
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California 94080
United States of America

(each referred to in this Assignment as "Assignor"), whose residence or mailing address information is listed above.

This Assignment is to:

Assignee: Maze Therapeutics, Inc.
Address: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions in:

APOL1 INHIBITORS AND METHODS OF USE

which are set forth in:

Serial No.: 63/400,359 Filing Date: August 23, 2022
(which identifying information may be added after execution)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may

be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.



4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: <u>1/10/23</u>	Signature: <u></u>	<u>Patrick Sang Tae Lee</u>
Date: _____	Signature: _____	<u>Todd Jonathan August Ewing</u>
Date: <u>1/9/23</u>	Signature: <u></u>	<u>Adam Neil Reid</u>
Date: <u>1/10/23</u>	Signature: <u></u>	<u>Christopher Joseph Sinz</u>
Date: <u>1/10/23</u>	Signature: <u></u>	<u>Brong Zhang</u>
Date: <u>1/9/23</u>	Signature: <u></u>	<u>Sarah M. Bronner</u>

be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).



ASSIGNOR(s):

Date: _____	Signature: _____	Patrick Sang-Tae Lee
Date: <u>01/09/2023</u>	Signature: _____	Todd Jonathan August Ewing
Date: _____	Signature: _____	Adam Neil Reid
Date: _____	Signature: _____	Christopher Joseph Sinz
Date: _____	Signature: _____	Birong Zhang
Date: _____	Signature: _____	Sarah M. Bronner


Date: _____	Signature: _____	David John Morgans, Jr.
Date: _____	Signature: _____	Maarten Hoek
Date: <u>01/09/23</u>	Signature: <u>Victoria Anne Assimon</u>	Victoria Anne Assimon
Date: _____	Signature: _____	Chris Ziebenhaus
Date: _____	Signature: _____	Alexander Wayne Schammel

ASSIGNEE:

Date: _____	Signature: _____	Name: _____
		Title: _____
		Company: Maze Therapeutics, Inc.

Date: 1/10/23 Signature: 
David John Morgans, Jr.
Date: 1/10/23 Signature: 
Maarten Hoek
Date: _____ Signature: _____
Victoria Anne Assimon
Date: 1/9/23 Signature: 
Chris Ziebenhaus
Date: 1/9/23 Signature: 
Alexander Wayne Schammel

ASSIGNEE:

Date: 1/12/23 Signature: 
Name: Atul Dandekar
Title: Chief Strategy Officer
Company: Maze Therapeutics, Inc.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JANUARY 19, 2023

PTAS

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

507699464

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 01/17/2023

REEL/FRAME: 062400/0580
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 79275-30004.04

ASSIGNOR:

LEE, PATRICK SANG TAE

DOC DATE: 01/10/2023

ASSIGNOR:

EWING, TODD JONATHAN AUGUST

DOC DATE: 01/09/2023

ASSIGNOR:

REID, ADAM NEIL

DOC DATE: 01/09/2023

ASSIGNOR:

SINZ, CHRISTOPHER JOSEPH

DOC DATE: 01/10/2023

ASSIGNOR:

ZHANG, BIRONG

DOC DATE: 01/10/2023

ASSIGNOR:

BRONNER, SARAH M.

DOC DATE: 01/09/2023

ASSIGNOR:

MORGANS, DAVID JOHN, JR.

DOC DATE: 01/10/2023

ASSIGNOR:
HOEK, MAARTEN

DOC DATE: 01/10/2023

ASSIGNOR:
ASSIMON, VICTORIA ANNE

DOC DATE: 01/09/2023

ASSIGNOR:
ZIEBENHAUS, CHRIS

DOC DATE: 01/09/2023

ASSIGNOR:
SCHAMMEL, ALEXANDER WAYNE

DOC DATE: 01/09/2023

ASSIGNEE:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 63422341

FILING DATE: 11/03/2022

PATENT NUMBER:

ISSUE DATE:

TITLE: APOL1 INHIBITORS AND METHODS OF USE

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7746608

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PATRICK SANG TAE LEE	01/10/2023
TODD JONATHAN AUGUST EWING	01/09/2023
ADAM NEIL REID	01/09/2023
CHRISTOPHER JOSEPH SINZ	01/10/2023
BIRONG ZHANG	01/10/2023
SARAH M. BRONNER	01/09/2023
DAVID JOHN MORGANS JR.	01/10/2023
MAARTEN HOEK	01/10/2023
VICTORIA ANNE ASSIMON	01/09/2023
CHRIS ZIEBENHAUS	01/09/2023
ALEXANDER WAYNE SCHAMMEL	01/09/2023
RECEIVING PARTY DATA	
Name:	MAZE THERAPEUTICS, INC.
Street Address:	171 OYSTER POINT BLVD, SUITE 300
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	63422341
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 648-4782
Email:	nmendoza@mofo.com
Correspondent Name:	MARK MCBRIAR
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	200 CLARENDON STREET, 21ST FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02116

ASSIGNMENT

This assignment is by:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
4. Christopher Joseph Sinz
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
7. David John Morgans, Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300
South San Francisco, California 94080
United States of America
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
South San Francisco California
United States of America
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California 94080
United States of America

(each referred to in this Assignment as "Assignor"), whose residence or mailing address information is listed above.

This Assignment is to:

Assignee: Maze Therapeutics, Inc.
Address: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions in:

APOL1 INHIBITORS AND METHODS OF USE

which are set forth in:

Serial No.: 63/422,341 Filing Date: November 3, 2022
(which identifying information may be added after execution)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.






4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: <u>1/10/23</u>	Signature: 	Patrick Sang Tae Lee
Date: <u>1/10/23</u>	Signature: 	Todd Jonathan August Ewing
Date: <u>1/9/23</u>	Signature: 	Adam Neil Reid
Date: <u>1/10/23</u>	Signature: 	Christopher Joseph Sinz
Date: <u>1/10/23</u>	Signature: 	Birong Zhang
Date: <u>1/9/23</u>	Signature: 	Sarah M. Bronner
Date: <u>1/10/23</u>	Signature: 	David John Morgans, Jr.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).


ASSIGNOR(s):

Date: _____	Signature: _____	Patrick Song Tae Lee
Date: <u>01-09-2023</u>	Signature: _____	Todd Jonathan August Ewing
Date: _____	Signature: _____	Adam Neil Reid
Date: _____	Signature: _____	Christopher Joseph Sinz
Date: _____	Signature: _____	Birong Zhang
Date: _____	Signature: _____	Sarah M. Bronner
Date: _____	Signature: _____	David John Morgans, Jr.


Date:	_____	Signature:	_____
Date:	<u>02/09/23</u>	Signature:	<u>Maarten Hoek</u>
Date:	_____	Signature:	<u>Victoria Anne Assimon</u>
Date:	_____	Signature:	<u>Victoria Anne Assimon</u>
Date:	_____	Signature:	<u>Chris Ziebenhaus</u>
Date:	_____	Signature:	<u>Alexander Wayne Schammel</u>


ASSIGNEE:

Date:	_____	Signature:	_____
		Name:	_____
		Title:	_____
		Company:	Maze Therapeutics, Inc.

Date: 1/10/23 Signature: 
Maarten Hoek

Date: _____ Signature: _____


Date: 1/9/23 Signature: 
Victoria Anne Assimon

Date: 1/9/23 Signature: 
Chris Ziebenhaus

Date: _____ Signature: _____

Alexander Wayne Schammel

ASSIGNEE:

Date: 1/12/23 Signature: 

Name: Atul Dandekar
Title: Chief Strategy Officer
Company: Maze Therapeutics, Inc.

TRADUCCIÓN

PTAS

19 DE ENERO DE 2023

507699473

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS
UNIDOS NOTIFICACIÓN DE INSCRIPCIÓN DE DOCUMENTO
DE CESIÓN

EL DOCUMENTO ADJUNTO HA SIDO REGISTRADO POR LA OFICINA DE REGISTRO DE CESIONES DE LA OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS UNIDOS. UNA COPIA COMPLETA ESTÁ DISPONIBLE EN LA SALA DE BÚSQUEDA DE CESIONES EN EL CARRETE Y NÚMERO DE FOTOGRAMA QUE SE INDICAN A CONTINUACIÓN.

POR FAVOR, REVISE TODA LA INFORMACIÓN CONTENIDA EN ESTE AVISO. LA INFORMACIÓN CONTENIDA EN ESTE AVISO DE INSCRIPCIÓN REFLEJA LOS DATOS PRESENTES EN EL SISTEMA DE CESIÓN DE PATENTES Y MARCAS. SI ENCUENTRA ALGÚN ERROR O TIENE ALGUNA PREGUNTA SOBRE ESTE AVISO, PUEDE PONERSE EN CONTACTO CON LA OFICINA DE INSCRIPCIÓN DE CESIONES LLAMANDO AL 571-272-3350. SÍRVASE ENVIAR LA SOLICITUD DE CORRECCIÓN A: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

FECHA DE REGISTRO: 17/01/2023 REEL/FRAME : 062400/0616
NÚMERO DE PÁGINAS: 8

RESUMEN: CESIÓN DE INTERESES DEL CEDENTE (VÉASE EL DOCUMENTO PARA
MÁS DETALLES). NÚMERO DE EXPEDIENTE: 79275-30004.00

CEDENTE: LEE, PATRICK SANG TAE FECHA: 01/10/2023

CEDENTE:
EWING, TODD JONATHAN AUGUST

CEDENTE: REID, ADAM NEIL FECHA: 01/09/2023

CEDENTE: SINZ, CHRISTOPHER JOSEPH FECHA: 01/10/2023

CEDENTE:
ZHANG, BIRONG

CEDENTE:
BRONNER, SARAH M. FECHA: 01/09/2023

CEDENTE: MORGANS, DAVID JOHN, JR. FECHA: 01/10/2023

CEDENTE:
HOEK, MAARTEN

FECHA: 01/10/2023

CEDENTE:
ASSIMON, VICTORIA ANNE

FECHA: 01/09/2023

CEDENTE:
ZIEBENHAUS, CHRIS

FECHA: 01/09/2023

CEDENTE:
SCHAMMEL, ALEXANDER WAYNE

FECHA: 01/09/2023

CESIONARIO:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

NÚMERO DE SOLICITUD: 63300592 FECHA DE PRESENTACIÓN: 01/18/2022

NÚMERO DE PATENTE: FECHA DE EXPEDICIÓN:

TÍTULO: INHIBIDORES DE APOL1 Y MÉTODOS DE USO

DIVISIÓN DE REGISTROS PÚBLICOS

PORTADA DE CESIÓN DE PATENTES

Versión electrónica
v1.1 Versión de la hoja
de estilo v1.2

EPAS ID: PAT7746617

TIPO DE PRESENTACIÓN:	NUEVA CESIÓN
NATURALEZA DE LA TRANSMISIÓN:	CESIÓN

TRANSMISIÓN DE LOS DATOS DE LAS PARTES

Nombre	Fecha de ejecución
PATRICK SANG TAE LEE	01/10/2023
TODD JONATHAN AUGUST EWING	01/09/2023
ADAM NEIL REID	01/09/2023
CHRISTOPHER JOSEPH SINZ	01/10/2023
BIRONG ZHANG	01/10/2023
SARAH M. BRONNER	01/09/2023
DAVID JOHN MORGANS JR.	01/10/2023
MAARTEN HOEK	01/10/2023
VICTORIA ANNE ASSIMON	01/09/2023
CHRIS ZIEBENHAUS	01/09/2023
ALEXANDER WAYNE SCHAMMEL	01/09/2023

DATOS DE LA PARTE RECEPTORA

Nombre:	MAZE THERAPEUTICS, INC.
Dirección postal:	171 OYSTER POINT BLVD, SUITE 300
Ciudad:	SUR DE SAN FRANCISCO
Estado/País:	CALIFORNIA
Código postal:	94080

NÚMEROS DE PROPIEDAD Total: 1

Tipo de propiedad	Número
Número de solicitud:	63300592

DATOS DE CORRESPONDENCIA

Número de fax: (650)494-0792

La correspondencia se enviará primero a la dirección de correo electrónico, si no se consigue, se enviará utilizando un número de fax, si se ha facilitado; si no se consigue, se enviará por correo postal.

Tel: (617) 648-4782

Correo electrónico:

nmendoza@mofo.com

Corresponsal Nombre: MARK MCBRIAR

Dirección línea 1: MORRISON & FOERSTER LLP

Dirección Línea 2:	200 CLARENDON STREET, 21ST FLOOR
Dirección línea 4:	BOSTON, MASSACHUSETTS 02116

CESIÓN

Esta cesión es de:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
4. Christopher Joseph Sinz
171 Oyster Point Blvd, Suite 300
South San Francisco, California 54080
Estados Unidos de América
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
7. David John Morgans Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco California
Estados Unidos de América
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California
94080
Estados Unidos de América

(cada uno de ellos denominado en la presente Cesión "Cedente"), cuya dirección de residencia o postal figura más arriba. La presente Cesión se dirige a:

Cesionario: Maze Therapeutics, Inc.
Dirección: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
Una entidad jurídica debidamente constituida con arreglo a las leyes de:

(denominada en la presente Cesión "Cesionaria"), quien desea adquirir la totalidad de los derechos, títulos e intereses sobre y en virtud de la solicitud de patente identificada a continuación y las invenciones cubiertas por la misma.

El cedente inventó ciertas invenciones nuevas y útiles en:

INHIBIDORES DE APOL1 Y MÉTODOS DE USO

que se exponen en:

Número de serie: 63/300.592 Fecha de presentación: 18/01/2022
(es posible que se añada información identificativa después de la ejecución)

Por una buena y valiosa contraprestación, cuya recepción y suficiencia se reconocen por la presente, y en la medida en que el Cedente no lo haya hecho ya mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, o si el Cedente ya lo ha hecho mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, entonces en confinamiento de cualquier obligación de hacerlo en dicho acuerdo previo,

1. Por la presente, el Cedente vende, cede, transfiere y transfiere al Cesionario, sus sucesores, representantes legales y cesionarios, la totalidad de los derechos, títulos e intereses del Cedente sobre las invenciones antes mencionadas, la solicitud de patente, todas y cada una de las solicitudes no provisionales, las divisiones, las continuaciones y las continuaciones en parte que reivindiquen la prioridad de las mismas o el beneficio de las mismas, y todos y cada uno de los títulos de patente en los Estados Unidos de América y las sustituciones de las mismas, las continuaciones, y las continuaciones-en-parte reclaman prioridad a la misma o el beneficio de la misma, sustituciones de dichas solicitudes, y todas y cada una de las cartas patentes o patentes en los Estados Unidos de América y todos los países o jurisdicciones anteriores que puedan ser concedidas por la misma y sobre la misma, incluidas, sin limitación alguna, cualesquiera modificaciones de dichas cartas patentes, tales como reemisiones, reexámenes u otros procedimientos posteriores a la concesión, así como todas y cada una de las extensiones de dichas cartas patentes, y todos los derechos en virtud del Convenio Internacional para la Protección de la Propiedad Industrial, los derechos que ostentará y disfrutará el Cesionario (incluido cualquier derecho a entablar acciones y a recuperar daños y perjuicios por infracciones pasadas, presentes y futuras, así como todos y cada uno de los derechos a reivindicar prioridad sobre dicha solicitud y dicha

patente), todas y cada una de las solicitudes que reivindiquen derechos de propiedad intelectual o que se basen en dichas invenciones), para su propio uso y para el uso de sus derechohabientes, representantes legales y cesionarios hasta el final del plazo de vigencia de las licencias para las que se puedan conceder cartas patentes, de la misma forma y en su totalidad que el Cedente las habría autorizado y disfrutado si se hubiera realizado su cesión.

2. El Cedente declara, garantiza y acuerda (a) que, en el momento de la ejecución y entrega del presente contrato, el Cedente es el propietario y el titular del derecho real del Cedente. El cesionario es el propietario y el titular de todos los derechos e intereses del cesionario sobre dichas invenciones derivados de la solicitud de patente del cedente, y que el cedente es el único y legítimo propietario de todos los derechos, títulos e intereses del cedente sobre dichas invenciones derivadas del consentimiento del cedente sobre las mismas y de dicha solicitud de patente, y que los mismos estaban libres de cargas y que el Cedente previamente vendió, cedió, transfirió y traspasó, al Cesionario, sus sucesores, representantes legales y cesionarios, o a un predecesor en interés del Cesionario, la totalidad del derecho, título e interés del Cedente sobre dichas invenciones y dichas solicitudes de patente.

3. El Cedente firmará, ejecutará y entregará sin demora al Cesionario todos los documentos, instrumentos, declaraciones juradas y documentos, prestará todos los juramentos legales y realizará todos los actos necesarios o útiles para la obtención, el mantenimiento y la conservación de los títulos para el Cesionario, a costo del Cesionario, sus sucesores, representantes legales y cede, en cada caso, incluyendo, sin limitación, todo lo relacionado con (a) dichas invenciones o dicha solicitud de patente; (b) cualquier solicitud no provisional, división, continuación o continuación en parte que reivindique la prioridad de las mismas o el beneficio de las mismas, o cualquier sustitución de dicha solicitud; o (c) una carta patente o patentes para dichas invenciones en cualquier país o jurisdicción, incluyendo, sin limitación, cualquier modificación a dicha carta patente o patentes, tales como a través de reexpedición, reexamen u otro procedimiento posterior a la concesión. A los efectos de este párrafo. "obtención, mantenimiento, ejecución, defensa" incluirá, sin limitación, cualquier preparación, tramitación, procedimiento previo a la concesión y procedimiento posterior a la concesión, ya sea ante una oficina de patentes u otro organismo administrativo o judicial con jurisdicción en la materia.

4. Por la presente, el Cedente autoriza y solicita al Comisionado de Patentes de los Estados Unidos que expida las mencionadas cartas patentes de los Estados Unidos y cualquier reedición, reexamen, revisión o extensión a favor y en nombre del Cesionario como titular de dichas invenciones y de las cartas patentes vitalicias que se expidan sobre las mismas para uso exclusivo del Cesionario, sus sucesores, sus representantes legales y sus cesionarios.

5. Por la presente, el Cedente otorga a los abogados, a todos o a Morrison A Foerster LLP (o, según sea necesario, a los abogados o al país aplicable designados y autorizados por Morrison A Foerster LLP), la facultad de insertar en esta firma cualquier otra información que pueda ser necesaria o conveniente para cumplir con las normas de la Oficina de Patentes y Marcas de los Estados Unidos o de cualquier organismo extranjero de expedición de patentes para el registro de este documento. Incluyendo la posibilidad de inscribir en esta cesión el número de solicitud y fecha de presentación de dicha solicitud.

6. Esta cesión podrá ser firmada en uno o más ejemplares, con el mismo contenido que si cada uno de los firmantes lo hiciera en el mismo documento. Cada carta recapitulativa así ejecutada se considerará original, y todas las cartas recapitulativas se considerarán iguales y constituirán un único acuerdo.

En fe de lo cual, firmado por el infrascrito en la(s) fecha(s) opuesta(s) a lo(s) nombre(s) infrascrita(s).

CEDENTE(s):

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Todd Jonathan August Ewing

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Patrick Sang Tae Lee

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Adam Neil Reid

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Christopher Joseph Sinz

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Birong Zhang

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Victoria Anne Assimon

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Sarah M Bronner

Fecha: 01-10-2023 Firma: (firmado)
Nombre: David John Morgans Jr.

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Maarten Hoek

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Chris Ziebenhaus

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Alexander Wayne Schammel

CESIONARIO:

Fecha: 01-12-2023 Firma: (firmado)
Nombre: Atul Dandekar
Cargo: Director de Estrategia
Compañía: Maze Therapeutics, Inc.

TRADUCCIÓN

PTAS

15 DE MAYO DE 2022

507278618

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS
UNIDOS NOTIFICACIÓN DE INSCRIPCIÓN DE DOCUMENTO
DE CESIÓN

EL DOCUMENTO ADJUNTO HA SIDO REGISTRADO POR LA OFICINA DE REGISTRO DE CESIONES DE LA OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS UNIDOS. UNA COPIA COMPLETA ESTÁ DISPONIBLE EN LA SALA DE BÚSQUEDA DE CESIONES EN EL CARRETE Y NÚMERO DE FOTOGRAMA QUE SE INDICAN A CONTINUACIÓN.

POR FAVOR, REVISE TODA LA INFORMACIÓN CONTENIDA EN ESTE AVISO. LA INFORMACIÓN CONTENIDA EN ESTE AVISO DE INSCRIPCIÓN REFLEJA LOS DATOS PRESENTES EN EL SISTEMA DE CESIÓN DE PATENTES Y MARCAS. SI ENCUENTRA ALGÚN ERROR O TIENE ALGUNA PREGUNTA SOBRE ESTE AVISO, PUEDE PONERSE EN CONTACTO CON LA OFICINA DE INSCRIPCIÓN DE CESIONES LLAMANDO AL 571-272-3350. SÍRVASE ENVIAR LA SOLICITUD DE CORRECCIÓN A: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

FECHA DE REGISTRO: 05/11/2022 REEL/FRAME : 059895/0136
NÚMERO DE PÁGINAS: 9

RESUMEN: CESIÓN DE INTERESES DEL CEDENTE (VÉASE EL DOCUMENTO PARA
MÁS DETALLES). NÚMERO DE EXPEDIENTE: 79275-30004.01

CEDENTE: LEE, PATRICK SANG TAE FECHA: 04/26/2022

CEDENTE:
EWING, TODD JONATHAN AUGUST

FECHA: 04/25/2022

CEDENTE: REID, ADAM NEIL FECHA: 04/26/2022

CEDENTE: SINZ, CHRISTOPHER JOSEPH FECHA: 04/26/2022

CEDENTE:
ZHANG, BIRONG

CEDENTE: BRONNER, SARAH M. FECHA: 04/26/2022

CEDENTE: MORGANS, DAVID JOHN, JR. FECHA: 04/26/2022

CEDENTE:
HOEK, MAARTEN

FECHA: 04/26/2022

CEDENTE:
ASSIMON, VICTORIA ANNE

FECHA: 04/26/2022

CEDENTE:
ZIEBENHAUS, CHRIS

FECHA: 04/26/2022

CEDENTE:
SCHAMMEL, ALEXANDER WAYNE

FECHA: 04/26/2022

CESIONARIO:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

NÚMERO DE SOLICITUD: 63311668 FECHA DE PRESENTACIÓN: 02/18/2022

NÚMERO DE PATENTE: FECHA DE EXPEDICIÓN:

TÍTULO: INHIBIDORES DE APOL1 Y MÉTODOS DE USO

DIVISIÓN DE REGISTROS PÚBLICOS

PORTADA DE CESIÓN DE PATENTES

Versión electrónica
v1.1 Versión de la hoja
de estilo v1.2

TIPO DE PRESENTACIÓN:	NUEVA CESIÓN
NATURALEZA DE LA TRANSMISIÓN:	CESIÓN

TRANSMISIÓN DE LOS DATOS DE LAS PARTES

Nombre	Fecha de ejecución
PATRICK SANG TAE LEE	04/26/2022
TODD JONATHAN AUGUST EWING	04/25/2022
ADAM NEIL REID	04/26/2022
CHRISTOPHER JOSEPH SINZ	04/26/2022
BIRONG ZHANG	04/26/2022
SARAH M. BRONNER	04/26/2022
DAVID JOHN MORGANS JR.	04/26/2022
MAARTEN HOEK	04/26/2022
VICTORIA ANNE ASSIMON	04/26/2022
CHRIS ZIEBENHAUS	04/26/2022
ALEXANDER WAYNE SCHAMMEL	04/26/2022

DATOS DE LA PARTE RECEPTORA

Nombre:	MAZE THERAPEUTICS, INC.
Dirección postal:	171 OYSTER POINT BLVD, SUITE 300
Ciudad:	SUR DE SAN FRANCISCO
Estado/País:	CALIFORNIA
Código postal:	94080

NÚMEROS DE PROPIEDAD Total: 1

Tipo de propiedad	Número
Número de solicitud:	63311668

DATOS DE CORRESPONDENCIA

Número de fax: (650)494-0792

La correspondencia se enviará primero a la dirección de correo electrónico, si no se consigue, se enviará utilizando un número de fax, si se ha facilitado; si no se consigue, se enviará por correo postal.

Tel: (617) 648-4782

Correo electrónico:

nmendoza@mofo.com

Corresponsal Nombre: MARK MCBRIAR

Dirección línea 1: MORRISON & FOERSTER LLP

Dirección Línea 2: 200 CLARENDON STREET, 21ST FLOOR
Dirección línea 4: BOSTON, MASSACHUSETTS 02116

NÚMERO DE EXPEDIENTE: 79275-30004.01
NOMBRE DE QUIEN PRESENTA: MARK MCBRIAR
Firma: /Mark McBriar/
Fecha: 05/11/2022

CESIÓN

Esta cesión es de:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
4. Christopher Joseph Sinz
171 Oyster Point Blvd, Suite 300
South San Francisco, California 54080
Estados Unidos de América
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
7. David John Morgans Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco California
Estados Unidos de América
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California
94080
Estados Unidos de América

(cada uno de ellos denominado en la presente Cesión "Cedente"), cuya dirección de residencia o postal figura más arriba. La presente Cesión se dirige a:

Cesionario: Maze Therapeutics, Inc.
Dirección: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
Una entidad jurídica debidamente constituida con arreglo a las leyes de:

(denominada en la presente Cesión "Cesionaria"), quien desea adquirir la totalidad de los derechos, títulos e intereses sobre y en virtud de la solicitud de patente identificada a continuación y las invenciones cubiertas por la misma.

El cedente inventó ciertas invenciones nuevas y útiles en:

INHIBIDORES DE APOL1 Y MÉTODOS DE USO

que se exponen en:

Número de serie: 63/311.668 Fecha de presentación: 18/02/2022
(es posible que se añada información identificativa después de la ejecución)

Por una buena y valiosa contraprestación, cuya recepción y suficiencia se reconocen por la presente, y en la medida en que el Cedente no lo haya hecho ya mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, o si el Cedente ya lo ha hecho mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, entonces en confinamiento de cualquier obligación de hacerlo en dicho acuerdo previo,

1. Por la presente, el Cedente vende, cede, transfiere y transfiere al Cesionario, sus sucesores, representantes legales y cesionarios, la totalidad de los derechos, títulos e intereses del Cedente sobre las invenciones antes mencionadas, la solicitud de patente, todas y cada una de las solicitudes no provisionales, las divisiones, las continuaciones y las continuaciones en parte que reivindiquen la prioridad de las mismas o el beneficio de las mismas, y todos y cada uno de los títulos de patente en los Estados Unidos de América y las sustituciones de las mismas, las continuaciones, y las continuaciones-en-parte reclaman prioridad a la misma o el beneficio de la misma, sustituciones de dichas solicitudes, y todas y cada una de las cartas patentes o patentes en los Estados Unidos de América y todos los países o jurisdicciones anteriores que puedan ser concedidas por la misma y sobre la misma, incluidas, sin limitación alguna, cualesquiera modificaciones de dichas cartas patentes, tales como reemisiones, reexámenes u otros procedimientos posteriores a la concesión, así como todas y cada una de las extensiones de dichas cartas patentes, y todos los derechos en virtud del Convenio Internacional para la Protección de la Propiedad Industrial, los derechos que ostentará y disfrutará el Cesionario (incluido cualquier derecho a entablar acciones y a recuperar daños y perjuicios por infracciones pasadas, presentes y futuras, así como todos y cada uno de los derechos a reivindicar prioridad sobre dicha solicitud y dicha

patente), todas y cada una de las solicitudes que reivindiquen derechos de propiedad intelectual o que se basen en dichas invenciones), para su propio uso y para el uso de sus derechohabientes, representantes legales y cesionarios hasta el final del plazo de vigencia de las licencias para las que se puedan conceder cartas patentes, de la misma forma y en su totalidad que el Cedente las habría autorizado y disfrutado si se hubiera realizado su cesión.

2. El Cedente declara, garantiza y acuerda (a) que, en el momento de la ejecución y entrega del presente contrato, el Cedente es el propietario y el titular del derecho real del Cedente. El cesionario es el propietario y el titular de todos los derechos e intereses del cesionario sobre dichas invenciones derivados de la solicitud de patente del cedente, y que el cedente es el único y legítimo propietario de todos los derechos, títulos e intereses del cedente sobre dichas invenciones derivadas del consentimiento del cedente sobre las mismas y de dicha solicitud de patente, y que los mismos estaban libres de cargas y que el Cedente previamente vendió, cedió, transfirió y traspasó, al Cesionario, sus sucesores, representantes legales y cesionarios, o a un predecesor en interés del Cesionario, la totalidad del derecho, título e interés del Cedente sobre dichas invenciones y dichas solicitudes de patente.

3. El Cedente firmará, ejecutará y entregará sin demora al Cesionario todos los documentos, instrumentos, declaraciones juradas y documentos, prestará todos los juramentos legales y realizará todos los actos necesarios o útiles para la obtención, el mantenimiento y la conservación de los títulos para el Cesionario, a costo del Cesionario, sus sucesores, representantes legales y cede, en cada caso, incluyendo, sin limitación, todo lo relacionado con (a) dichas invenciones o dicha solicitud de patente; (b) cualquier solicitud no provisional, división, continuación o continuación en parte que reivindique la prioridad de las mismas o el beneficio de las mismas, o cualquier sustitución de dicha solicitud; o (c) una carta patente o patentes para dichas invenciones en cualquier país o jurisdicción, incluyendo, sin limitación, cualquier modificación a dicha carta patente o patentes, tales como a través de reexpedición, reexamen u otro procedimiento posterior a la concesión. A los efectos de este párrafo. "obtención, mantenimiento, ejecución, defensa" incluirá, sin limitación, cualquier preparación, tramitación, procedimiento previo a la concesión y procedimiento posterior a la concesión, ya sea ante una oficina de patentes u otro organismo administrativo o judicial con jurisdicción en la materia.

4. Por la presente, el Cedente autoriza y solicita al Comisionado de Patentes de los Estados Unidos que expida las mencionadas cartas patentes de los Estados Unidos y cualquier reedición, reexamen, revisión o extensión a favor y en nombre del Cesionario como titular de dichas invenciones y de las cartas patentes vitalicias que se expidan sobre las mismas para uso exclusivo del Cesionario, sus sucesores, sus representantes legales y sus cesionarios.

5. Por la presente, el Cedente otorga a los abogados, a todos o a Morrison A Foerster LLP (o, según sea necesario, a los abogados o al país aplicable designados y autorizados por Morrison A Foerster LLP), la facultad de insertar en esta firma cualquier otra información que pueda ser necesaria o conveniente para cumplir con las normas de la Oficina de Patentes y Marcas de los Estados Unidos o de cualquier organismo extranjero de expedición de patentes para el registro de este documento. Incluyendo la posibilidad de inscribir en esta cesión el número de solicitud y fecha de presentación de dicha solicitud.

6. Esta cesión podrá ser firmada en uno o más ejemplares, con el mismo contenido que si cada uno de los firmantes lo hiciera en el mismo documento. Cada carta recapitulativa así ejecutada se considerará original, y todas las cartas recapitulativas se considerarán iguales y constituirán un único acuerdo.

En fe de lo cual, firmado por el infrascrito en la(s) fecha(s) opuesta(s) a lo(s) nombre(s) infrascrita(s).

CEDENTE(s):

Fecha: 04-26-2022 Firma: (firmado)
Nombre: Patrick Sang Tae Lee

Fecha: 04-26-2022 Firma: (firmado)
Nombre: Adam Neil Reid

Fecha: 04-26-2022 Firma: (firmado)
Nombre: Christopher Joseph Sinz

Fecha: 04-26-2022 Firma: (firmado)
Nombre: Birong Zhang

Fecha: 04-26-2022 Firma: (firmado)
Nombre: Sarah M Bronner

Fecha: 04-26-2022 Firma: (firmado)
Nombre: David John Morgans, Jr.

Fecha: 04-26-2022 Firma: (firmado)

Nombre: Maarten Hoek

Fecha: 04-25-2022 Firma: (firmado)

Nombre: Todd Jonathan August Ewing

Fecha: 04-26-2022 Firma: (firmado)

Nombre: Victoria Anne Assimon

Fecha: 04-26-2022 Firma: (firmado)

Nombre: Chris Ziebenhaus

Fecha: 04-26-2022 Firma: (firmado)

Nombre: Alexander Wayne Schammel

CESIONARIO:

Fecha: 05-02-2022 Firma: (firmado)

Nombre: Tara Nickerson

Cargo: Director de Negocios

Compañía: Maze Therapeutics, Inc.

TRADUCCIÓN

PTAS

19 DE ENERO DE 2023

507699470

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS
UNIDOS NOTIFICACIÓN DE INSCRIPCIÓN DE DOCUMENTO
DE CESIÓN

EL DOCUMENTO ADJUNTO HA SIDO REGISTRADO POR LA OFICINA DE REGISTRO DE CESIONES DE LA OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS UNIDOS. UNA COPIA COMPLETA ESTÁ DISPONIBLE EN LA SALA DE BÚSQUEDA DE CESIONES EN EL CARRETE Y NÚMERO DE FOTOGRAMA QUE SE INDICAN A CONTINUACIÓN.

POR FAVOR, REVISE TODA LA INFORMACIÓN CONTENIDA EN ESTE AVISO. LA INFORMACIÓN CONTENIDA EN ESTE AVISO DE INSCRIPCIÓN REFLEJA LOS DATOS PRESENTES EN EL SISTEMA DE CESIÓN DE PATENTES Y MARCAS. SI ENCUENTRA ALGÚN ERROR O TIENE ALGUNA PREGUNTA SOBRE ESTE AVISO, PUEDE PONERSE EN CONTACTO CON LA OFICINA DE INSCRIPCIÓN DE CESIONES LLAMANDO AL 571-272-3350. SÍRVASE ENVIAR LA SOLICITUD DE CORRECCIÓN A: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

FECHA DE REGISTRO: 01/17/2023 REEL/FRAME : 062400/0605
NÚMERO DE PÁGINAS: 8

RESUMEN: CESIÓN DE INTERESES DEL CEDENTE (VÉASE EL DOCUMENTO PARA
MÁS DETALLES). NÚMERO DE EXPEDIENTE: 79275-30004.02

CEDENTE: LEE, PATRICK SANG TAE FECHA: 01/10/2023

CEDENTE:
EWING, TODD JONATHAN AUGUST

CEDENTE: REID, ADAM NEIL FECHA: 01/09/2023

CEDENTE: SINZ, CHRISTOPHER JOSEPH FECHA: 01/10/2023

CEDENTE:
ZHANG, BIRONG

CEDENTE:
BRONNER, SARAH M. FECHA: 01/09/2023

CEDENTE: MORGANS, DAVID JOHN, JR. FECHA: 01/10/2023

CEDENTE:
HOEK, MAARTEN

FECHA: 01/10/2023

CEDENTE:
ASSIMON, VICTORIA ANNE

FECHA: 01/09/2023

CEDENTE:
ZIEBENHAUS, CHRIS

FECHA: 01/09/2023

CEDENTE:
SCHAMMEL, ALEXANDER WAYNE

FECHA: 01/09/2023

CESIONARIO:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

NÚMERO DE SOLICITUD: 63332553 FECHA DE PRESENTACIÓN:04/19/2022
NÚMERO DE PATENTE: FECHA DE EXPEDICIÓN:
TÍTULO: INHIBIDORES DE APOL1 Y MÉTODOS DE USO

DIVISIÓN DE REGISTROS PÚBLICOS

PORTADA DE CESIÓN DE PATENTES

Versión electrónica
v1.1 Versión de la hoja
de estilo v1.2

EPAS ID: PAT7746614

TIPO DE PRESENTACIÓN:	NUEVA CESIÓN
NATURALEZA DE LA TRANSMISIÓN:	CESIÓN

TRANSMISIÓN DE LOS DATOS DE LAS PARTES

Nombre	Fecha de ejecución
PATRICK SANG TAE LEE	01/10/2023
TODD JONATHAN AUGUST EWING	01/09/2023
ADAM NEIL REID	01/09/2023
CHRISTOPHER JOSEPH SINZ	01/10/2023
BIRONG ZHANG	01/10/2023
SARAH M. BRONNER	01/09/2023
DAVID JOHN MORGANS JR.	01/10/2023
MAARTEN HOEK	01/10/2023
VICTORIA ANNE ASSIMON	01/09/2023
CHRIS ZIEBENHAUS	01/09/2023
ALEXANDER WAYNE SCHAMMEL	01/09/2023

DATOS DE LA PARTE RECEPTORA

Nombre:	MAZE THERAPEUTICS, INC.
Dirección postal:	171 OYSTER POINT BLVD, SUITE 300
Ciudad:	SUR DE SAN FRANCISCO
Estado/País:	CALIFORNIA
Código postal:	94080

NÚMEROS DE PROPIEDAD Total: 1

Tipo de propiedad	Número
Número de solicitud:	63332553

DATOS DE CORRESPONDENCIA

Número de fax: (650)494-0792

La correspondencia se enviará primero a la dirección de correo electrónico, si no se consigue, se enviará utilizando un número de fax, si se ha facilitado; si no se consigue, se enviará por correo postal.

Tel: (617) 648-4782

Correo electrónico:

nmendoza@mofo.com

Corresponsal Nombre: MARK MCBRIAR

Dirección línea 1: MORRISON & FOERSTER LLP

Dirección Línea 2:	200 CLARENDON STREET, 21ST FLOOR
Dirección línea 4:	BOSTON, MASSACHUSETTS 02116

CESIÓN

Esta cesión es de:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
4. Christopher Joseph Sinz
171 Oyster Point Blvd, Suite 300
South San Francisco, California 54080
Estados Unidos de América
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
7. David John Morgans Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco California
Estados Unidos de América
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California
94080
Estados Unidos de América

(cada uno de ellos denominado en la presente Cesión "Cedente"), cuya dirección de residencia o postal figura más arriba. La presente Cesión se dirige a:

Cesionario: Maze Therapeutics, Inc.
Dirección: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
Una entidad jurídica debidamente constituida con arreglo a las leyes de:

(denominada en la presente Cesión "Cesionaria"), quien desea adquirir la totalidad de los derechos, títulos e intereses sobre y en virtud de la solicitud de patente identificada a continuación y las invenciones cubiertas por la misma.

El cedente inventó ciertas invenciones nuevas y útiles en:

INHIBIDORES DE APOL1 Y MÉTODOS DE USO

que se exponen en:

Número de serie: 63/332.553 Fecha de presentación: 19/04/2022
(es posible que se añada información identificativa después de la ejecución)

Por una buena y valiosa contraprestación, cuya recepción y suficiencia se reconocen por la presente, y en la medida en que el Cedente no lo haya hecho ya mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, o si el Cedente ya lo ha hecho mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, entonces en confinamiento de cualquier obligación de hacerlo en dicho acuerdo previo,

1. Por la presente, el Cedente vende, cede, transfiere y transfiere al Cesionario, sus sucesores, representantes legales y cesionarios, la totalidad de los derechos, títulos e intereses del Cedente sobre las invenciones antes mencionadas, la solicitud de patente, todas y cada una de las solicitudes no provisionales, las divisiones, las continuaciones y las continuaciones en parte que reivindiquen la prioridad de las mismas o el beneficio de las mismas, y todos y cada uno de los títulos de patente en los Estados Unidos de América y las sustituciones de las mismas, las continuaciones, y las continuaciones-en-parte reclaman prioridad a la misma o el beneficio de la misma, sustituciones de dichas solicitudes, y todas y cada una de las cartas patentes o patentes en los Estados Unidos de América y todos los países o jurisdicciones anteriores que puedan ser concedidas por la misma y sobre la misma, incluidas, sin limitación alguna, cualesquiera modificaciones de dichas cartas patentes, tales como reemisiones, reexámenes u otros procedimientos posteriores a la concesión, así como todas y cada una de las extensiones de dichas cartas patentes, y todos los derechos en virtud del Convenio Internacional para la Protección de la Propiedad Industrial, los derechos que ostentará y disfrutará el Cesionario (incluido cualquier derecho a entablar acciones y a recuperar daños y perjuicios por infracciones pasadas, presentes y futuras, así como todos y cada uno de los derechos a reivindicar prioridad sobre dicha solicitud y dicha

patente), todas y cada una de las solicitudes que reivindiquen derechos de propiedad intelectual o que se basen en dichas invenciones), para su propio uso y para el uso de sus derechohabientes, representantes legales y cesionarios hasta el final del plazo de vigencia de las licencias para las que se puedan conceder cartas patentes, de la misma forma y en su totalidad que el Cedente las habría autorizado y disfrutado si se hubiera realizado su cesión.

2. El Cedente declara, garantiza y acuerda (a) que, en el momento de la ejecución y entrega del presente contrato, el Cedente es el propietario y el titular del derecho real del Cedente. El cesionario es el propietario y el titular de todos los derechos e intereses del cesionario sobre dichas invenciones derivados de la solicitud de patente del cedente, y que el cedente es el único y legítimo propietario de todos los derechos, títulos e intereses del cedente sobre dichas invenciones derivadas del consentimiento del cedente sobre las mismas y de dicha solicitud de patente, y que los mismos estaban libres de cargas y que el Cedente previamente vendió, cedió, transfirió y traspasó, al Cesionario, sus sucesores, representantes legales y cesionarios, o a un predecesor en interés del Cesionario, la totalidad del derecho, título e interés del Cedente sobre dichas invenciones y dichas solicitudes de patente.

3. El Cedente firmará, ejecutará y entregará sin demora al Cesionario todos los documentos, instrumentos, declaraciones juradas y documentos, prestará todos los juramentos legales y realizará todos los actos necesarios o útiles para la obtención, el mantenimiento y la conservación de los títulos para el Cesionario, a costo del Cesionario, sus sucesores, representantes legales y cede, en cada caso, incluyendo, sin limitación, todo lo relacionado con (a) dichas invenciones o dicha solicitud de patente; (b) cualquier solicitud no provisional, división, continuación o continuación en parte que reivindique la prioridad de las mismas o el beneficio de las mismas, o cualquier sustitución de dicha solicitud; o (c) una carta patente o patentes para dichas invenciones en cualquier país o jurisdicción, incluyendo, sin limitación, cualquier modificación a dicha carta patente o patentes, tales como a través de reexpedición, reexamen u otro procedimiento posterior a la concesión. A los efectos de este párrafo. "obtención, mantenimiento, ejecución, defensa" incluirá, sin limitación, cualquier preparación, tramitación, procedimiento previo a la concesión y procedimiento posterior a la concesión, ya sea ante una oficina de patentes u otro organismo administrativo o judicial con jurisdicción en la materia.

4. Por la presente, el Cedente autoriza y solicita al Comisionado de Patentes de los Estados Unidos que expida las mencionadas cartas patentes de los Estados Unidos y cualquier reedición, reexamen, revisión o extensión a favor y en nombre del Cesionario como titular de dichas invenciones y de las cartas patentes vitalicias que se expidan sobre las mismas para uso exclusivo del Cesionario, sus sucesores, sus representantes legales y sus cesionarios.

5. Por la presente, el Cedente otorga a los abogados, a todos o a Morrison A Foerster LLP (o, según sea necesario, a los abogados o al país aplicable designados y autorizados por Morrison A Foerster LLP), la facultad de insertar en esta firma cualquier otra información que pueda ser necesaria o conveniente para cumplir con las normas de la Oficina de Patentes y Marcas de los Estados Unidos o de cualquier organismo extranjero de expedición de patentes para el registro de este documento. Incluyendo la posibilidad de inscribir en esta cesión el número de solicitud y fecha de presentación de dicha solicitud.

6. Esta cesión podrá ser firmada en uno o más ejemplares, con el mismo contenido que si cada uno de los firmantes lo hiciera en el mismo documento. Cada carta recapitulativa así ejecutada se considerará original, y todas las cartas recapitulativas se considerarán iguales y constituirán un único acuerdo.

En fe de lo cual, firmado por el infrascrito en la(s) fecha(s) opuesta(s) a lo(s) nombre(s) infrascrita(s).

CEDENTE(s):

Fecha: 1/10/2023 Firma: (firmado)
Nombre: Patrick Sang Tae Lee

Fecha: 1/09/2023 Firma: (firmado)
Nombre: Adam Neil Reid

Fecha: 1/10/2023 Firma: (firmado)
Nombre: Christopher Joseph Sinz

Fecha: 1/10/2023 Firma: (firmado)
Nombre: Birong Zhang

Fecha: 1/09/2023 Firma: (firmado)
Nombre: Sarah M. Bronner

Fecha: 1/10/2023 Firma: (firmado)
Nombre: David John Morgans, Jr.

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Todd Jonathan August Ewing

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Victoria Anne Assimon

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Maarten Hoek

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Chris Ziebenhaus

Fecha: 04-09-2023 Firma: (firmado)
Nombre: Alexander Wayne Schammel

CESIONARIO:

Fecha: 01-12-2023 Firma: (firmado)
Nombre: Atul Dandekar
Cargo: Director de Estrategia
Compañía: Maze Therapeutics, Inc.

TRADUCCIÓN

PTAS

19 DE ENERO DE 2023

507699466

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS
UNIDOS NOTIFICACIÓN DE INSCRIPCIÓN DE DOCUMENTO
DE CESIÓN

EL DOCUMENTO ADJUNTO HA SIDO REGISTRADO POR LA OFICINA DE REGISTRO DE CESIONES DE LA OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS UNIDOS. UNA COPIA COMPLETA ESTÁ DISPONIBLE EN LA SALA DE BÚSQUEDA DE CESIONES EN EL CARRETE Y NÚMERO DE FOTOGRAMA QUE SE INDICAN A CONTINUACIÓN.

POR FAVOR, REVISE TODA LA INFORMACIÓN CONTENIDA EN ESTE AVISO. LA INFORMACIÓN CONTENIDA EN ESTE AVISO DE INSCRIPCIÓN REFLEJA LOS DATOS PRESENTES EN EL SISTEMA DE CESIÓN DE PATENTES Y MARCAS. SI ENCUENTRA ALGÚN ERROR O TIENE ALGUNA PREGUNTA SOBRE ESTE AVISO, PUEDE PONERSE EN CONTACTO CON LA OFICINA DE INSCRIPCIÓN DE CESIONES LLAMANDO AL 571-272-3350. SÍRVASE ENVIAR LA SOLICITUD DE CORRECCIÓN A: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

FECHA DE REGISTRO: 17/01/2023 REEL/FRAME : 062400/0591
NÚMERO DE PÁGINAS: 8

RESUMEN: CESIÓN DE INTERESES DEL CEDENTE (VÉASE EL DOCUMENTO PARA
MÁS DETALLES). NÚMERO DE EXPEDIENTE: 79275-30004.03

CEDENTE:
LEE, PATRICK SANG TAE

CEDENTE:
EWING, TODD JONATHAN AUGUST

CEDENTE: REID, ADAM NEIL FECHA: 01/09/2023

CEDENTE: SINZ, CHRISTOPHER JOSEPH FECHA: 01/10/2023

CEDENTE:
ZHANG, BIRONG

CEDENTE:
BRONNER, SARAH M. FECHA: 01/09/2023

CEDENTE: MORGANS, DAVID JOHN, JR. FECHA: 01/10/2023

CEDENTE:
HOEK, MAARTEN

FECHA: 01/10/2023

CEDENTE:
ASSIMON, VICTORIA ANNE

FECHA: 01/09/2023

CEDENTE:
ZIEBENHAUS, CHRIS

FECHA: 01/09/2023

CEDENTE:
SCHAMMEL, ALEXANDER WAYNE

FECHA: 01/09/2023

CESIONARIO:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

NÚMERO DE SOLICITUD: 63400359 FECHA DE PRESENTACIÓN: 08/23/2022

NÚMERO DE PATENTE: FECHA DE EXPEDICIÓN:

TÍTULO: INHIBIDORES DE APOL1 Y MÉTODOS DE USO

DIVISIÓN DE REGISTROS PÚBLICOS

PORTADA DE CESIÓN DE PATENTES

Versión electrónica
v1.1 Versión de la hoja
de estilo v1.2

EPAS ID: PAT7746610

TIPO DE PRESENTACIÓN:	NUEVA CESIÓN
NATURALEZA DE LA TRANSMISIÓN:	CESIÓN

TRANSMISIÓN DE LOS DATOS DE LAS PARTES

Nombre	Fecha de ejecución
PATRICK SANG TAE LEE	01/10/2023
TODD JONATHAN AUGUST EWING	01/09/2023
ADAM NEIL REID	01/09/2023
CHRISTOPHER JOSEPH SINZ	01/10/2023
BIRONG ZHANG	01/10/2023
SARAH M. BRONNER	01/09/2023
DAVID JOHN MORGANS JR.	01/10/2023
MAARTEN HOEK	01/10/2023
VICTORIA ANNE ASSIMON	01/09/2023
CHRIS ZIEBENHAUS	01/09/2023
ALEXANDER WAYNE SCHAMMEL	01/09/2023

DATOS DE LA PARTE RECEPTORA

Nombre:	MAZE THERAPEUTICS, INC.
Dirección postal:	171 OYSTER POINT BLVD, SUITE 300
Ciudad:	SUR DE SAN FRANCISCO
Estado/País:	CALIFORNIA
Código postal:	94080

NÚMEROS DE PROPIEDAD Total: 1

Tipo de propiedad	Número
Número de solicitud:	63400359

DATOS DE CORRESPONDENCIA

Número de fax: (650)494-0792

La correspondencia se enviará primero a la dirección de correo electrónico, si no se consigue, se enviará utilizando un número de fax, si se ha facilitado; si no se consigue, se enviará por correo postal.

Tel: (617) 648-4782

Correo electrónico:

nmendoza@mofo.com

Corresponsal Nombre: MARK MCBRIAR

Dirección línea 1: MORRISON & FOERSTER LLP

Dirección Línea 2:	200 CLARENDON STREET, 21ST FLOOR
Dirección línea 4:	BOSTON, MASSACHUSETTS 02116

CESIÓN

Esta cesión es de:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
4. Christopher Joseph Sinz
171 Oyster Point Blvd, Suite 300
South San Francisco, California 54080
Estados Unidos de América
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
7. David John Morgans Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco California
Estados Unidos de América
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California
94080
Estados Unidos de América

(cada uno de ellos denominado en la presente Cesión "Cedente"), cuya dirección de residencia o postal figura más arriba. La presente Cesión se dirige a:

Cesionario: Maze Therapeutics, Inc.
Dirección: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
Una entidad jurídica debidamente constituida con arreglo a las leyes de:

(denominada en la presente Cesión "Cesionaria"), quien desea adquirir la totalidad de los derechos, títulos e intereses sobre y en virtud de la solicitud de patente identificada a continuación y las invenciones cubiertas por la misma.

El cedente inventó ciertas invenciones nuevas y útiles en:

INHIBIDORES DE APOL1 Y MÉTODOS DE USO

que se exponen en:

Número de serie: 63/400.359 Fecha de presentación: 23/08/2022
(es posible que se añada información identificativa después de la ejecución)

Por una buena y valiosa contraprestación, cuya recepción y suficiencia se reconocen por la presente, y en la medida en que el Cedente no lo haya hecho ya mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, o si el Cedente ya lo ha hecho mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, entonces en confinamiento de cualquier obligación de hacerlo en dicho acuerdo previo,

1. Por la presente, el Cedente vende, cede, transfiere y transfiere al Cesionario, sus sucesores, representantes legales y cesionarios, la totalidad de los derechos, títulos e intereses del Cedente sobre las invenciones antes mencionadas, la solicitud de patente, todas y cada una de las solicitudes no provisionales, las divisiones, las continuaciones y las continuaciones en parte que reivindiquen la prioridad de las mismas o el beneficio de las mismas, y todos y cada uno de los títulos de patente en los Estados Unidos de América y las sustituciones de las mismas, las continuaciones, y las continuaciones-en-parte reclaman prioridad a la misma o el beneficio de la misma, sustituciones de dichas solicitudes, y todas y cada una de las cartas patentes o patentes en los Estados Unidos de América y todos los países o jurisdicciones anteriores que puedan ser concedidas por la misma y sobre la misma, incluidas, sin limitación alguna, cualesquiera modificaciones de dichas cartas patentes, tales como reemisiones, reexámenes u otros procedimientos posteriores a la concesión, así como todas y cada una de las extensiones de dichas cartas patentes, y todos los derechos en virtud del Convenio Internacional para la Protección de la Propiedad Industrial, los derechos que ostentará y disfrutará el Cesionario (incluido cualquier derecho a entablar acciones y a recuperar daños y perjuicios por infracciones pasadas, presentes y futuras, así como todos y cada uno de los derechos a reivindicar prioridad sobre dicha solicitud y dicha

patente), todas y cada una de las solicitudes que reivindiquen derechos de propiedad intelectual o que se basen en dichas invenciones), para su propio uso y para el uso de sus derechohabientes, representantes legales y cesionarios hasta el final del plazo de vigencia de las licencias para las que se puedan conceder cartas patentes, de la misma forma y en su totalidad que el Cedente las habría autorizado y disfrutado si se hubiera realizado su cesión.

2. El Cedente declara, garantiza y acuerda (a) que, en el momento de la ejecución y entrega del presente contrato, el Cedente es el propietario y el titular del derecho real del Cedente. El cesionario es el propietario y el titular de todos los derechos e intereses del cesionario sobre dichas invenciones derivados de la solicitud de patente del cedente, y que el cedente es el único y legítimo propietario de todos los derechos, títulos e intereses del cedente sobre dichas invenciones derivadas del consentimiento del cedente sobre las mismas y de dicha solicitud de patente, y que los mismos estaban libres de cargas y que el Cedente previamente vendió, cedió, transfirió y traspasó, al Cesionario, sus sucesores, representantes legales y cesionarios, o a un predecesor en interés del Cesionario, la totalidad del derecho, título e interés del Cedente sobre dichas invenciones y dichas solicitudes de patente.

3. El Cedente firmará, ejecutará y entregará sin demora al Cesionario todos los documentos, instrumentos, declaraciones juradas y documentos, prestará todos los juramentos legales y realizará todos los actos necesarios o útiles para la obtención, el mantenimiento y la conservación de los títulos para el Cesionario, a costo del Cesionario, sus sucesores, representantes legales y cede, en cada caso, incluyendo, sin limitación, todo lo relacionado con (a) dichas invenciones o dicha solicitud de patente; (b) cualquier solicitud no provisional, división, continuación o continuación en parte que reivindique la prioridad de las mismas o el beneficio de las mismas, o cualquier sustitución de dicha solicitud; o (c) una carta patente o patentes para dichas invenciones en cualquier país o jurisdicción, incluyendo, sin limitación, cualquier modificación a dicha carta patente o patentes, tales como a través de reexpedición, reexamen u otro procedimiento posterior a la concesión. A los efectos de este párrafo. "obtención, mantenimiento, ejecución, defensa" incluirá, sin limitación, cualquier preparación, tramitación, procedimiento previo a la concesión y procedimiento posterior a la concesión, ya sea ante una oficina de patentes u otro organismo administrativo o judicial con jurisdicción en la materia.

4. Por la presente, el Cedente autoriza y solicita al Comisionado de Patentes de los Estados Unidos que expida las mencionadas cartas patentes de los Estados Unidos y cualquier reedición, reexamen, revisión o extensión a favor y en nombre del Cesionario como titular de dichas invenciones y de las cartas patentes vitalicias que se expidan sobre las mismas para uso exclusivo del Cesionario, sus sucesores, sus representantes legales y sus cesionarios.

5. Por la presente, el Cedente otorga a los abogados, a todos o a Morrison A Foerster LLP (o, según sea necesario, a los abogados o al país aplicable designados y autorizados por Morrison A Foerster LLP), la facultad de insertar en esta firma cualquier otra información que pueda ser necesaria o conveniente para cumplir con las normas de la Oficina de Patentes y Marcas de los Estados Unidos o de cualquier organismo extranjero de expedición de patentes para el registro de este documento. Incluyendo la posibilidad de inscribir en esta cesión el número de solicitud y fecha de presentación de dicha solicitud.

6. Esta cesión podrá ser firmada en uno o más ejemplares, con el mismo contenido que si cada uno de los firmantes lo hiciera en el mismo documento. Cada carta recapitulativa así ejecutada se considerará original, y todas las cartas recapitulativas se considerarán iguales y constituirán un único acuerdo.

En fe de lo cual, firmado por el infrascrito en la(s) fecha(s) opuesta(s) a lo(s) nombre(s) infrascrita(s).

CEDENTE(s):

Fecha: 01-10-2023 Firma: (firmado)

Nombre: Patrick Sang Tae Lee

Fecha: 01-09-2023 Firma: (firmado)

Nombre: Adam Neil Reid

Fecha: 01-10-2023 Firma: (firmado)

Nombre: Christopher Joseph Sinz

Fecha: 01-10-2023 Firma: (firmado)

Nombre: Birong Zhang

Fecha: 01-09-2023 Firma: (firmado)

Nombre: Sarah M. Bronner

Fecha: 01-09-2023 Firma: (firmado)

Nombre: Todd Jonathan August Ewing

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Victoria Anne Assimon

Fecha: 01-10-2023 Firma: (firmado)
Nombre: David John Morgans, Jr.

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Maarten Hoek

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Chris Ziebenhaus

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Alexander Wayne Schammel

CESIONARIO:

Fecha: 01-12-2023 Firma: (firmado)
Nombre: Atul Dandekar
Cargo: Director de Estrategia
Compañía: Maze Therapeutics, Inc.

TRADUCCIÓN

PTAS

19 DE ENERO DE 2023

507699464

MARK MCBRIAR
MORRISON & FOERSTER LLP
200 CLARENDON STREET, 21ST FLOOR
BOSTON, MA 02116

OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS
UNIDOS NOTIFICACIÓN DE INSCRIPCIÓN DE DOCUMENTO
DE CESIÓN

EL DOCUMENTO ADJUNTO HA SIDO REGISTRADO POR LA OFICINA DE REGISTRO DE CESIONES DE LA OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS UNIDOS. UNA COPIA COMPLETA ESTÁ DISPONIBLE EN LA SALA DE BÚSQUEDA DE CESIONES EN EL CARRETE Y NÚMERO DE FOTOGRAMA QUE SE INDICAN A CONTINUACIÓN.

POR FAVOR, REVISE TODA LA INFORMACIÓN CONTENIDA EN ESTE AVISO. LA INFORMACIÓN CONTENIDA EN ESTE AVISO DE INSCRIPCIÓN REFLEJA LOS DATOS PRESENTES EN EL SISTEMA DE CESIÓN DE PATENTES Y MARCAS. SI ENCUENTRA ALGÚN ERROR O TIENE ALGUNA PREGUNTA SOBRE ESTE AVISO, PUEDE PONERSE EN CONTACTO CON LA OFICINA DE INSCRIPCIÓN DE CESIONES LLAMANDO AL 571-272-3350. SÍRVASE ENVIAR LA SOLICITUD DE CORRECCIÓN A: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

FECHA DE REGISTRO: 17/01/2023 REEL/FRAME : 062400/0580
NÚMERO DE PÁGINAS: 8

RESUMEN: CESIÓN DE INTERESES DEL CEDENTE (VÉASE EL DOCUMENTO PARA
MÁS DETALLES). NÚMERO DE EXPEDIENTE: 79275-30004.03

CEDENTE:
LEE, PATRICK SANG TAE

CEDENTE:
EWING, TODD JONATHAN AUGUST

CEDENTE: REID, ADAM NEIL FECHA: 01/09/2023

CEDENTE: SINZ, CHRISTOPHER JOSEPH FECHA: 01/10/2023

CEDENTE:
ZHANG, BIRONG

CEDENTE:
BRONNER, SARAH M. FECHA: 01/09/2023

CEDENTE: MORGANS, DAVID JOHN, JR. FECHA: 01/10/2023

CEDENTE:
HOEK, MAARTEN

FECHA: 01/10/2023

CEDENTE:
ASSIMON, VICTORIA ANNE

FECHA: 01/09/2023

CEDENTE:
ZIEBENHAUS, CHRIS

FECHA: 01/09/2023

CEDENTE:
SCHAMMEL, ALEXANDER WAYNE

FECHA: 01/09/2023

CESIONARIO:
MAZE THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CALIFORNIA
94080

NÚMERO DE SOLICITUD: 63422341 FECHA DE PRESENTACIÓN: 11/03/2022

NÚMERO DE PATENTE: FECHA DE EXPEDICIÓN:

TÍTULO: INHIBIDORES DE APOL1 Y MÉTODOS DE USO

DIVISIÓN DE REGISTROS PÚBLICOS

PORTADA DE CESIÓN DE PATENTES

Versión electrónica
v1.1 Versión de la hoja
de estilo v1.2

EPAS ID: PAT7746608

TIPO DE PRESENTACIÓN:	NUEVA CESIÓN
NATURALEZA DE LA TRANSMISIÓN:	CESIÓN

TRANSMISIÓN DE LOS DATOS DE LAS PARTES

Nombre	Fecha de ejecución
PATRICK SANG TAE LEE	01/10/2023
TODD JONATHAN AUGUST EWING	01/09/2023
ADAM NEIL REID	01/09/2023
CHRISTOPHER JOSEPH SINZ	01/10/2023
BIRONG ZHANG	01/10/2023
SARAH M. BRONNER	01/09/2023
DAVID JOHN MORGANS JR.	01/10/2023
MAARTEN HOEK	01/10/2023
VICTORIA ANNE ASSIMON	01/09/2023
CHRIS ZIEBENHAUS	01/09/2023
ALEXANDER WAYNE SCHAMMEL	01/09/2023

DATOS DE LA PARTE RECEPTORA

Nombre:	MAZE THERAPEUTICS, INC.
Dirección postal:	171 OYSTER POINT BLVD, SUITE 300
Ciudad:	SUR DE SAN FRANCISCO
Estado/País:	CALIFORNIA
Código postal:	94080

NÚMEROS DE PROPIEDAD Total: 1

Tipo de propiedad	Número
Número de solicitud:	63422341

DATOS DE CORRESPONDENCIA

Número de fax: (650)494-0792

La correspondencia se enviará primero a la dirección de correo electrónico, si no se consigue, se enviará utilizando un número de fax, si se ha facilitado; si no se consigue, se enviará por correo postal.

Tel: (617) 648-4782

Correo electrónico:

nmendoza@mofo.com

Corresponsal Nombre: MARK MCBRIAR

Dirección línea 1: MORRISON & FOERSTER LLP

Dirección Línea 2:	200 CLARENDON STREET, 21ST FLOOR
Dirección línea 4:	BOSTON, MASSACHUSETTS 02116

CESIÓN

Esta cesión es de:

1. Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
2. Todd Jonathan August Ewing
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
3. Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
4. Christopher Joseph Sinz
171 Oyster Point Blvd, Suite 300
South San Francisco, California 54080
Estados Unidos de América
5. Birong Zhang
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
6. Sarah M. Bronner
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
7. David John Morgans Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
8. Maarten Hoek
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América

9. Victoria Anne Assimon
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
10. Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco California
Estados Unidos de América
11. Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California
94080
Estados Unidos de América

(cada uno de ellos denominado en la presente Cesión "Cedente"), cuya dirección de residencia o postal figura más arriba. La presente Cesión se dirige a:

Cesionario: Maze Therapeutics, Inc.
Dirección: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
Una entidad jurídica debidamente constituida con arreglo a las leyes de:

(denominada en la presente Cesión "Cesionaria"), quien desea adquirir la totalidad de los derechos, títulos e intereses sobre y en virtud de la solicitud de patente identificada a continuación y las invenciones cubiertas por la misma.

El cedente inventó ciertas invenciones nuevas y útiles en:

INHIBIDORES DE APOL1 Y MÉTODOS DE USO

que se exponen en:

Número de serie: 63/422.341 Fecha de presentación: 03/11/2022
(es posible que se añada información identificativa después de la ejecución)

Por una buena y valiosa contraprestación, cuya recepción y suficiencia se reconocen por la presente, y en la medida en que el Cedente no lo haya hecho ya mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, o si el Cedente ya lo ha hecho mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, entonces en confinamiento de cualquier obligación de hacerlo en dicho acuerdo previo,

1. Por la presente, el Cedente vende, cede, transfiere y transfiere al Cesionario, sus sucesores, representantes legales y cesionarios, la totalidad de los derechos, títulos e intereses del Cedente sobre las invenciones antes mencionadas, la solicitud de patente, todas y cada una de las solicitudes no provisionales, las divisiones, las continuaciones y las continuaciones en parte que reivindiquen la prioridad de las mismas o el beneficio de las mismas, y todos y cada uno de los títulos de patente en los Estados Unidos de América y las sustituciones de las mismas, las continuaciones, y las continuaciones-en-parte reclaman prioridad a la misma o el beneficio de la misma, sustituciones de dichas solicitudes, y todas y cada una de las cartas patentes o patentes en los Estados Unidos de América y todos los países o jurisdicciones anteriores que puedan ser concedidas por la misma y sobre la misma, incluidas, sin limitación alguna, cualesquiera modificaciones de dichas cartas patentes, tales como reemisiones, reexámenes u otros procedimientos posteriores a la concesión, así como todas y cada una de las extensiones de dichas cartas patentes, y todos los derechos en virtud del Convenio Internacional para la Protección de la Propiedad Industrial, los derechos que ostentará y disfrutará el Cesionario (incluido cualquier derecho a entablar acciones y a recuperar daños y perjuicios por infracciones pasadas, presentes y futuras, así como todos y cada uno de los derechos a reivindicar prioridad sobre dicha solicitud y dicha

patente), todas y cada una de las solicitudes que reivindiquen derechos de propiedad intelectual o que se basen en dichas invenciones), para su propio uso y para el uso de sus derechohabientes, representantes legales y cesionarios hasta el final del plazo de vigencia de las licencias para las que se puedan conceder cartas patentes, de la misma forma y en su totalidad que el Cedente las habría autorizado y disfrutado si se hubiera realizado su cesión.

2. El Cedente declara, garantiza y acuerda (a) que, en el momento de la ejecución y entrega del presente contrato, el Cedente es el propietario y el titular del derecho real del Cedente. El cesionario es el propietario y el titular de todos los derechos e intereses del cesionario sobre dichas invenciones derivados de la solicitud de patente del cedente, y que el cedente es el único y legítimo propietario de todos los derechos, títulos e intereses del cedente sobre dichas invenciones derivadas del consentimiento del cedente sobre las mismas y de dicha solicitud de patente, y que los mismos estaban libres de cargas y que el Cedente previamente vendió, cedió, transfirió y traspasó, al Cesionario, sus sucesores, representantes legales y cesionarios, o a un predecesor en interés del Cesionario, la totalidad del derecho, título e interés del Cedente sobre dichas invenciones y dichas solicitudes de patente.

3. El Cedente firmará, ejecutará y entregará sin demora al Cesionario todos los documentos, instrumentos, declaraciones juradas y documentos, prestará todos los juramentos legales y realizará todos los actos necesarios o útiles para la obtención, el mantenimiento y la conservación de los títulos para el Cesionario, a costo del Cesionario, sus sucesores, representantes legales y cede, en cada caso, incluyendo, sin limitación, todo lo relacionado con (a) dichas invenciones o dicha solicitud de patente; (b) cualquier solicitud no provisional, división, continuación o continuación en parte que reivindique la prioridad de las mismas o el beneficio de las mismas, o cualquier sustitución de dicha solicitud; o (c) una carta patente o patentes para dichas invenciones en cualquier país o jurisdicción, incluyendo, sin limitación, cualquier modificación a dicha carta patente o patentes, tales como a través de reexpedición, reexamen u otro procedimiento posterior a la concesión. A los efectos de este párrafo. "obtención, mantenimiento, ejecución, defensa" incluirá, sin limitación, cualquier preparación, tramitación, procedimiento previo a la concesión y procedimiento posterior a la concesión, ya sea ante una oficina de patentes u otro organismo administrativo o judicial con jurisdicción en la materia.

4. Por la presente, el Cedente autoriza y solicita al Comisionado de Patentes de los Estados Unidos que expida las mencionadas cartas patentes de los Estados Unidos y cualquier reedición, reexamen, revisión o extensión a favor y en nombre del Cesionario como titular de dichas invenciones y de las cartas patentes vitalicias que se expidan sobre las mismas para uso exclusivo del Cesionario, sus sucesores, sus representantes legales y sus cesionarios.

5. Por la presente, el Cedente otorga a los abogados, a todos o a Morrison A Foerster LLP (o, según sea necesario, a los abogados o al país aplicable designados y autorizados por Morrison A Foerster LLP), la facultad de insertar en esta firma cualquier otra información que pueda ser necesaria o conveniente para cumplir con las normas de la Oficina de Patentes y Marcas de los Estados Unidos o de cualquier organismo extranjero de expedición de patentes para el registro de este documento. Incluyendo la posibilidad de inscribir en esta cesión el número de solicitud y fecha de presentación de dicha solicitud.

6. Esta cesión podrá ser firmada en uno o más ejemplares, con el mismo contenido que si cada uno de los firmantes lo hiciera en el mismo documento. Cada carta recapitulativa así ejecutada se considerará original, y todas las cartas recapitulativas se considerarán iguales y constituirán un único acuerdo.

En fe de lo cual, firmado por el infrascrito en la(s) fecha(s) opuesta(s) a lo(s) nombre(s) infrascrita(s).

CEDENTE(s):

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Patrick Sang Tae Lee

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Adam Neil Reid

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Christopher Joseph Sinz

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Birong Zhang

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Sarah M. Bronner

Fecha: 01-10-2023 Firma: (firmado)
Nombre: David John Morgans, Jr.

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Todd Jonathan August Ewing

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Victoria Anne Assimon

Fecha: 01-10-2023 Firma: (firmado)
Nombre: Maarten Hoek

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Chris Ziebenhaus

Fecha: 01-09-2023 Firma: (firmado)
Nombre: Alexander Wayne Schammel

CESIONARIO:

Fecha: 01-12-2023 Firma: (firmado)
Nombre: Atul Dandekar
Cargo: Director de Estrategia
Compañía: Maze Therapeutics, Inc.